Published in Eur J Endocrinol on July 01, 2004
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut (2011) 2.14
Multimodal management of neuroendocrine liver metastases. HPB (Oxford) (2010) 1.21
Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendocrine neoplasms: A single-institution analysis (1995-2012) in South China. BMC Endocr Disord (2012) 1.11
From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin (2009) 1.10
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res (2010) 1.01
Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol (2009) 0.96
Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature. World J Gastroenterol (2005) 0.93
Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol (2011) 0.90
Therapy for metastatic pancreatic neuroendocrine tumors. Ann Transl Med (2014) 0.86
A review of the use of somatostatin analogs in oncology. Onco Targets Ther (2013) 0.83
Established and potential therapeutic applications of octreotide in palliative care. Support Care Cancer (2008) 0.82
Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. Oncologist (2016) 0.77
Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life. Oncotarget (2016) 0.76
Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med (2015) 0.76
Management of the hormonal syndrome of neuroendocrine tumors. Arch Med Sci (2016) 0.75
New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol (2017) 0.75
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol (2003) 2.36
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res (2007) 2.16
Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res (2008) 1.98
18F-FDG PET/CT Diagnosis of Bronchopulmonary Carcinoids Versus Pulmonary Hamartomas. Clin Nucl Med (2016) 1.94
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J Clin Endocrinol Metab (2013) 1.69
Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol (2008) 1.68
N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol (2002) 1.59
Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet (2004) 1.58
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol (2005) 1.57
Gastrinoma (duodenal and pancreatic). Neuroendocrinology (2007) 1.55
Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis. J Am Soc Nephrol (2009) 1.55
Hand-assisted retroperitoneoscopic live donor nephrectomy in comparison to open and laparoscopic procedures: a prospective study on donor morbidity and kidney function. Transplantation (2004) 1.49
Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study. Intensive Care Med (2012) 1.48
Assessment of inactive, active and mixed atherosclerotic plaques by 18F-FDG-PET; an age group-based correlation with cardiovascular risk factors. Int J Cardiovasc Imaging (2008) 1.45
Somatostatin receptor expression in non-medullary thyroid carcinomas. Hormones (Athens) (2012) 1.43
⁶⁸Ga-DOTA-TOC-PET/CT detects heart metastases from ileal neuroendocrine tumors. Endocrine (2013) 1.41
Recognizing genes differentially regulated in vitro by the multiple endocrine neoplasia type 1 (MEN1) gene, using RNA interference and oligonucleotide microarrays. Surgery (2006) 1.40
Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med (2002) 1.40
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology (2012) 1.38
Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg (2002) 1.35
Serum levels of 2,2',4,4',5,5'-hexachlorobiphenyl (CB-153) in relation to markers of reproductive function in young males from the general Swedish population. Environ Health Perspect (2003) 1.33
Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation (2007) 1.32
Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res (2003) 1.32
Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging (2009) 1.30
Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med (2012) 1.24
Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol (2010) 1.23
Affinity of galectin-8 and its carbohydrate recognition domains for ligands in solution and at the cell surface. Glycobiology (2007) 1.21
Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol (2010) 1.15
Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant (2007) 1.12
Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure. Circulation (2008) 1.12
In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol (2010) 1.12
[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab (2006) 1.11
The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci (2002) 1.09
Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg (2012) 1.07
Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation (2007) 1.05
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol (2014) 1.05
Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg (2008) 1.05
Naturally occurring human genetic variation in the 3'-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and hypertension in a sex-dependent fashion. J Am Coll Cardiol (2008) 1.05
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology (2009) 1.04
Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. J Histochem Cytochem (2004) 1.03
Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology (2009) 1.03
Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol (2012) 1.02
Development of abdominal fat and incipient metabolic syndrome in young healthy men exposed to long-term stress. Nutr Metab Cardiovasc Dis (2006) 1.02
Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol (2010) 1.02
Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med (2013) 1.01
Endocrine responses to nocturnal eating--possible implications for night work. Eur J Nutr (2003) 1.01
Mutational tuning of galectin-3 specificity and biological function. J Biol Chem (2010) 1.01
In vivo and in vitro characterization of [18F]-FE-(+)-DTBZ as a tracer for beta-cell mass. Nucl Med Biol (2010) 1.01
Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol (2005) 1.00
Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis (2012) 0.99
Granins and granin-related peptides in neuroendocrine tumours. Regul Pept (2010) 0.98
Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab (2007) 0.98
A panel of 11 region-specific radioimmunoassays for measurements of human chromogranin A. Regul Pept (2004) 0.97
Quantitative imaging of serotonergic biosynthesis and degradation in the endocrine pancreas. J Nucl Med (2014) 0.97
Malignant gastric ghrelinoma with hyperghrelinemia. J Clin Endocrinol Metab (2004) 0.97
High 18F-FDG Uptake in synthetic aortic vascular grafts on PET/CT in symptomatic and asymptomatic patients. J Nucl Med (2008) 0.97
High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg (2008) 0.97
Enlargement of secretory vesicles by protein tyrosine phosphatase PTP-MEG2 in rat basophilic leukemia mast cells and Jurkat T cells. J Immunol (2002) 0.96
Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control (2006) 0.95
Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol (2007) 0.95
Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med (2013) 0.95
Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg (2002) 0.94
Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma. Theranostics (2012) 0.94
C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions. Angew Chem Int Ed Engl (2005) 0.94
Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg (2002) 0.94
Associations between CB-153 and p,p'-DDE and hormone levels in serum in middle-aged and elderly men. Chemosphere (2006) 0.94
Natriuretic peptides in unstable coronary artery disease. Eur Heart J (2004) 0.93
Neuroendocrine inhibition of glucose production and resistance to cancer in dwarf mice. Exp Gerontol (2008) 0.93
Expression of trkB in human neuroblastoma in relation to MYCN expression and retinoic acid treatment. Lab Invest (2003) 0.93
Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens (2010) 0.93
Metabolic responses to nocturnal eating in men are affected by sources of dietary energy. J Nutr (2002) 0.93
Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol (2008) 0.92
Transfection of the multiple endocrine neoplasia type 1 gene to a human endocrine pancreatic tumor cell line inhibits cell growth and affects expression of JunD, delta-like protein 1/preadipocyte factor-1, proliferating cell nuclear antigen, and QM/Jif-1. J Clin Endocrinol Metab (2004) 0.92
An ancestral variant of Secretogranin II confers regulation by PHOX2 transcription factors and association with hypertension. Hum Mol Genet (2007) 0.92
POP levels in breast milk and maternal serum and thyroid hormone levels in mother-child pairs from Uppsala, Sweden. Environ Int (2009) 0.91
Pain, disability and coping reflected in the diurnal cortisol variability in patients scheduled for lumbar disc surgery. Eur J Pain (2008) 0.91
Prognostic relevance of survivin in pancreatic endocrine tumors. World J Surg (2012) 0.91
Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre. Lung Cancer (2013) 0.90